First Manhattan CO Bellus Health Inc. Transaction History

First Manhattan CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$2.27 - $3.3 $1.99 Million - $2.89 Million	-876,732 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$8.88 - $11.15 $3.57 Million - $4.49 Million	-402,555 Reduced 31.47%	876,732 $9.02 Million
Q1 2020 May 06, 2020	SELL	$5.77 - $10.85 $4.81 Million - $9.05 Million	-834,039 Reduced 39.47%	1,279,287 $12.8 Million
Q4 2019 Feb 13, 2020	SELL	$5.76 - $7.6 $2.45 Million - $3.23 Million	-425,000 Reduced 16.74%	2,113,326 $16.1 Million
Q3 2019 Nov 13, 2019	BUY	$6.24 - $8.84 $15.8 Million - $22.4 Million	2,538,326 New	2,538,326 $16.2 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.